Submission is free of charge and must be completed online only via the ESC Abstract Submission platform. Abstracts and clinical cases sent by email will not be accepted.
Abstracts and clinical cases must be submitted by the submission deadline, which is Monday 30 January 2023, 12:00PM noon CET/Paris Time. Late submissions will not be accepted; abstracts/clinical cases still in Draft status after the deadline will not be considered.
The ESC currently does not allow submissions exclusively from Institutions in the Russian Federation and/or Belarus. However collaborative research may be submitted and (if accepted) presented by co-authors from other countries.
Draft status - If you do not click on the submit button (Step 4 of the abstract submission service), your abstract/clinical case will be saved in Draft Status. You will then be able to review it and submit it later before the deadline.
NB: Abstracts/Clinical cases that are in draft status after the deadline cannot be processed and therefore will not be considered for selection.
Changes and corrections - Once submitted, it is not possible to make any corrections to the abstract/clinical case content or information (such as authors list and details, topic, conclusion(s) etc...). The ESC is not authorised to make changes to a submission. In order to correct your abstract/clinical case, you must withdraw it and submit a new version prior to the deadline (See below for withdrawal procedure). Note that, such replacement of your abstract/clinical case is not possible after the deadline. In the case of errors in your abstract/clinical case discovered after the deadline, you may indicate the correction on your presentation. However, changes will not be included in the publications. If accepted, your abstract/clinical case will be published as submitted.
Withdrawal - If you want to withdraw an abstract/clinical case already submitted, please notify us as quickly as possible at firstname.lastname@example.org stating the submission title and number.
Withdrawals are still accepted after the submission deadline.
Step 1: Submission Information
Title - A maximum of 200 characters typed in lower-case letters, except for abbreviations and study names. Please be careful that your title might be truncated if you copy and paste it into the field. Do not include authors, institutions, city names, trademarks and abbreviations in the title.
Topic - At the time of the submission, the submitter must select one single topic to index the abstract/clinical case.
It is important to carefully select the best matching topic as this choice will determine under which area the abstract/clinical case will be reviewed and graded.
Therefore, submitters should consider all potential options available before selecting the submission topic.
The topic list is organised by main topics and several layers of subtopics to maximise precision. An appropriate choice for the main topic and first subheadings is more important than your choice for the lowest layers of subtopics.
If the abstract/clinical case is accepted, the presenter will be required to select three additional topics/keywords at the time of the upload. These are important to optimise indexing of the abstract/clinical case in the programme and in ESC 365, the cardiology knowledge hub. This serves to optimise search results and enhance the visibility of the research.
Note that in order to view the topic list, you must first select the ESC event for which you are submitting (first field of the page).
COVID-19 and cardiovascular disease - Please indicate here if your research relates to COVID-19 and cardiovascular disease.
Category – If you wish to submit a clinical case, please select the dedicated category -
- Clinical case
Please note that if a clinical case is not submitted under this category – It will be automatically categorised as such by the abstract services.
Options: Only available for abstract submissions
You may wish to submit your abstract under the following option -
- Doctoral Student
This option is reserved for doctoral students enrolled in doctoral coursework and working towards their degree. If your abstract is accepted an award certificate of scholarship will be asked.
On behalf of - You may use this field to enter the name of the affiliation for your research or the name of an investigating team. Do not use this field to list individual authors.
Affiliation/investigating teams will not be listed in the authors' index of the Scientific Programme but will appear in publications.
Trial Registration number - If available, indicate any reference to your trial registration.
Project code/Grant number - If any, please use this field to enter the information.
Funding acknowledgements - All sources of financial support (including government grants) for this research must be filed under this heading and not in the abstract text. All grant funding agency abbreviations should be spelt out. This information will be published in the abstract itself.
The submitter is asked to indicate the type of funding source(s) and name it/them, if any.
This information may be used in the context of ESC research projects.
Step 2: Authors and Institutions
Your abstract/clinical case must list at least one author in order to be submitted.
Authors' list -
Please note that the first author should be the Presenter by default. Nevertheless, it can be modified at the time of results announcement through the agreement form online available in March 2023. In all cases, the Presenter must be part of the authors list included in the submission and be able to explain his/her role in the research during presentation.
You may enter up to 15 authors in the authors list including the Presenter.
If you have more than 15 authors, you can use the “On behalf of” field (see above) to enter the name of an investigating team/study group.
The names of authors will be published as listed on the submission form. Please make sure you have entered the full list of authors - Official contributors in the research submitted - and that the information given for each author is correct, as no changes will be possible after the abstract/clinical case is submitted (see paragraph on changes and corrections above).
The authors’ order and details (names, cities, country codes) will be published as entered by the submitter.
An author may not revise or resubmit an abstract/clinical case in order to make changes or corrections after this deadline; instead, the abstract/clinical case may be withdrawn or, if accepted, the error may be indicated during the presentation. Adding or removing authors after the submission deadline is not permitted.
The submitter certifies and warranties to the ESC that the list of authors is complete and that he/she has permission from all persons he/she enters as co-authors to be listed in this abstract/clinical case and that they are aware that their names will appear in all publications.
If the assigned presenter does not upload the abstract/clinical case presentation in its required format by the Upload deadline (24 May 2022) – the abstract/clinical case will be automatically withdrawn and removed from the scientific programme and related publications.
Institutions - This is a mandatory step. All participating institutions should be listed as applicable. You will be requested to select your institution when you create the presenter and the authors. Once you have entered your city, a list will automatically appear from which you can select your institution. If your institution is not on the list, you have the possibility of creating it. If your city is not on the list, please enter it, press 'enter' and then add your institution.
All abstracts/clinical cases must be submitted (and will be presented) in English using UK English spelling with accurate grammar and spelling suitable for publication. If in doubt, please arrange for the review of your submission by a native English speaker, by a university scientific publications office (or other similar facility) prior to submission.
Submitted abstracts/clinical cases must contain original material neither published nor presented elsewhere. Please refer to embargo policy below.
Submissions that indicate “the work is in progress” or “the results will be announced / discussed in the presentation” cannot be accepted as the reviewing committee needs full information to grade the submission and therefore will not be validated for the selection process.
Abstract submitted on animal studies: Study must follow the "Principles of laboratory animal care" (NIH Publication no. 85-23 revised 1985) and according to the national law if applicable.
Do not cut and paste symbols into your text. Use the symbols provided when you click on the Omega button (Ω).
We recommend you structure your abstract using the following headings:
We recommend you structure your clinical case using the following headings:
- Patient presentation
- Initial work-up
- Diagnosis and management
- Conclusion(s) - Take home messages/Learning points
Important note to clinical case submitters – Patient confidentiality and patient consent -
You are responsible for removing any elements that could be used to identify patients. All the content of the case submission, including the text, its title and media files must have been stripped of all personal information that could be used to identify the patient.
In addition, it is the authors responsibility to ensure that they have obtained all necessary consent(s), approvals and authorisations in connection with the Case submitted to the ESC with the patient and any organisation involved (Hospital, Clinic ...).
There is not a specific maximum of words, but rather a maximum total size of the submission (shown as 100 %), including the text with spaces. The maximum abstract size is 35 lines (3 000 characters).
Use the save and refresh button at the bottom in order to display the size of the abstract/clinical case in percentage (shown on the left of the screen). The system converts the size in % when you save it as a draft.
The character limit does not include the title and the authors. Only the abstract text and spaces are taken into account.
In addition to your text, you can add up to 2 pictures.
Should you wish to insert a table in your submission, you need to upload it as a picture.
Your picture file(s) must meet the following criteria:
Size: less than 2 MB
Measures no larger than 1920 pixels(x) x 1080 pixels(y)
The title field for each picture is optional.
Submitters are responsible for the pictures uploaded – Please make sure that your picture(s) is(are) correctly uploaded and readable on the preview (this represents how the reviewers will see it and how it will look in all publications). It is the responsibility of the submitter to ensure the quality of the attachment(s) is suitable for publications - if not, picture(s) of insufficient quality may be deleted.
Important: As the grading and selection process is blind, the title and body text must not contain identifying features, i.e., information such as:
- Names (authors or others)
- Names of the institutes (hospitals, medical schools, clinics…)
Also not authorised
- Trademarks. The use of commercial drug names, brands and registered trademarks is strictly prohibited. Instead, use generic drug names. Drugs should be referred to by their active substances or pharmacological designations.
- Company names and locations.
- Websites and email addresses.
Failure to comply with the above requirements will/may lead to automatic rejection of the submission, or this information may be deleted by the abstract services, and some rephrasing may occur.
Furthermore, the Abstract Reviewing Committee (graders) is required to identify abstracts pertaining to commercial promotion of a proprietary product, to notify the selection committee.
Do not include grant acknowledgements in the abstract content. Use the appropriate field (see funding acknowledgement section above).
References/Citations: You may use this field to enter references and/or citations you need to insert in your submission. Do not list references/citations in the body text.
Keywords: Do not enter keywords in your submission, as you will enter these at the time of the upload of the presentation.
Limit use of acronyms and abbreviations. Define at first use with acronym or abbreviation in parentheses. Place abbreviations in parentheses after the full word the first time it appears. Abbreviations increase the difficulty of reading and evaluating abstracts/clinical cases, which will be considered in the review process. Only commonly used abbreviations should appear in the title of the abstract/clinical case.
Do not include copyright or trademark symbols.
Please note that any medical research involving human subjects must conform to the principles of the Declaration of Helsinki of the World Medical Association. If any human experimentation is undertaken, the presenting author must be able to provide copies of informed consents signed by human participants. We remind you that patient’s photo should be avoided, and the patient must never be identifiable in your presentation.
Step 4: Preview and Submission
Proofread abstracts/clinical cases carefully to avoid errors before submission, check spelling and grammar. The abstract/clinical case will be reviewed and published (if accepted) as it has been submitted – No Exceptions!
Do not forget to click on the 'submit' button to validate your submission. After having submitted your abstract/clinical case, you will receive an immediate automatic confirmation by email (please make sure to state your correct email address!) notifying you of the abstract/clinical case number. Please use this reference in all correspondence. If you do not receive this confirmation, please contact email@example.com.
There is no limit to the number of abstracts/clinical cases an author/individual may submit, but the same research/case cannot be submitted twice/in separate abstracts, even under a different topic/category or with a different title. If you submit two abstracts/clinical cases with the same content, the Abstract Submission Services will automatically keep the most recent submission and withdraw the other. Note that duplicate drafts will not be deleted.
All abstracts/clinical cases will be blinded for review by 7 to 10 members of the Reviewing Committee (graders). Each grader is selected by the Congress Programme Committee to review abstracts/clinical cases in the topics that best fits their expertise.
Our intent is to be most inclusive of the quality science received without compromising scientific integrity.
NB - The Abstract Reviewing Committee (graders) is required to identify abstracts pertaining to commercial promotion of a proprietary product, to notify the selection committee.
Abstracts submitted for consideration must be an original idea, concept, or an improvement or revision of a previous idea. Submissions are peer-reviewed for scientific content, logical presentation, and current interest of the topic to the scientific community.
The final selection will be made by the Selection Committee in March 2023 that will determine the format and schedule of presentation for each abstract/clinical case. No rescheduling or changes will be possible.
Accepted abstracts will be scheduled either as oral presentations, or poster presentations.
Accepted clinical cases will be scheduled as oral presentations.
Presentation and Interaction on the research will be conducted in English. Presenters are expected to speak / write good English.
All submitters will be notified early March about the outcome (accepted or not accepted) of the review and selection process. Please ensure that the email provided is accurate as all correspondences will be sent via email.
If the abstract/clinical case is accepted, further instructions will be provided at the time of results announcement.
Submission of an abstract/clinical case constitutes a formal commitment by the author(s) to present the work, in person in Edinburgh, if accepted. Failure to upload and register for the Congress by the set deadline (Wednesday 24 May 2023) will lead to the withdrawal of the abstract/clinical case from the scientific programme and all Congress publications (including the online congress platform, the abstract supplement and ESC365).
The same presenter cannot be assigned to more than 3 abstracts/clinical cases - co-authors should then be assigned as presenters.
All expenses (registration, airfare, hotel....) associated with the submission and presentation of an abstract/clinical case, are under the responsibility of the presenter.
All presented abstracts/clinical cases will be published in the online abstract supplement of the European Journal of Cardiovascular Nursing, in July 2023.
Accepted abstracts/clinical cases are under embargo until one week before the congress. At that time, they will be available on ESC 365 via the online Scientific Programme.
Abstracts selected for an ESC Press Release will remain under embargo until the beginning of the scheduled presentation. Abstract content will be released thereafter.
Submitted abstracts/clinical cases should not be published in any other journals and/or online publications or presented at any international congresses.
Breaking of the Embargo Policy by a presenter or co-author will lead to the Withdrawal of the abstract//clinical case submission and presentation from the ESC Press Conference and/or Scientific Programme and retraction from all ESC publications.
For more information about the ESC Media and Embargo Policy, please consult the full version online - https://www.escardio.org/The-ESC/Press-Office/ESC-Media-and-Embargo-Policy
Affirmation of originality and copyright transfer statement
By submitting your work to the ESC
- You consent to have authors’ names, affiliation and biographical material used in connection with the publication of your work.
- Author(s) represents and warrants to the ESC that he/she/they is/are sole author(s) of the work, that all authors have participated in and agree with the content and conclusions of the work, and that the work is original and does not infringe upon any copyright, proprietary, or personal right of any third party.
The submitter hereby affirms that the work submitted is original, except for extracts from copyrighted works fully authorised by the copyright holders, and that all statements declared as facts are based on thorough examination and investigation for accurateness.
- Submitted abstracts/clinical cases should not have been published in any other journals and/or online publications nor presented at any previous international congress. However, former presentation at national meetings and/or non-cardiovascular specialists’ meetings does not disqualify.
A submitter, presenter or co-author submitting or presenting published work will lead to the withdrawal of the abstract/presentation from the Press Conference and/or Scientific Programme.
- Submitted abstracts must report new information not previously published or presented at a national or international scientific meeting prior to the Congress. Note that abstracts previously presented at meetings will not be accepted unless there is a substantial update of data.
The content belongs to the author(s). However, if the abstract/clinical case is accepted the submitter agrees, on behalf of all co-authors, to transfer and assign to the ESC free of charge, on a non-exclusive basis, for twenty years from the present submission the rights to edit, publish, reproduce, reformat, distribute in whole or in part the abstract/clinical case and prepare all type of derivative works such as press releases and/or educational products, using all communication tools and means, now known or hereinafter developed, including any and all digital means and any and all supports or forms of media, now known or hereinafter developed, in particular all paper, analog, digital, numerical and electronic media, including Internet, Intranet and Extranet sites and social media. This includes use in indexes or search databases in print, electronic, or other media.
Authors retain the right, after presentation, to subsequently include the work in articles, books, or derivative works that he/she authors or edits, provided said use does not imply the endorsement of the ESC.
The submitter signs for all co-authors. He/she accepts responsibility for the present rules for submission and presentation on behalf of all co-authors.
Disclosure Policy/Conflict(s) of interest
The Congress Programme Committee requests all presenters to disclose their potential conflict(s) of interest at the time of acceptance of presentation (agreement form submission).
It is also the responsibility of the presenter to disclose any potential conflict(s) of interest from co-authors pertaining to the presentation on the presentation itself (as may be required).
This will allow the audience to take potential conflicts of interest into account when assessing the objectivity of the presentation.
A potential conflict of interest may arise from various relationships, past or present, such as employment, consultancy, investments and stock ownership, funding for research, family relationship, etc.
All related potential conflicts of interest must be stated.
This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the article. Such relationships include, but are not limited to, employment by an industrial concern, ownership of stock, membership on a standing advisory council or committee, being on the board of directors, or being publicly associated with the company or its products. Other areas of real or perceived conflict of interest could include receiving honoraria or consulting fees or receiving grants or funds from such corporations or individuals representing such corporations.
By certifying that you have read these Submission rules, you also confirm having received the prior approval from the co-authors to provide their data to the ESC. The information collected in this CALL FOR ABSTRACTS AND CLINICAL CASES is subject to data processing to proceed with the elaboration of ACNAP 2023 abstract and clinical case programme. It is a statutory requirement to list the authors who have contributed to the research submitted. Authors not listed in the submission will not be acknowledged in the abstract/clinical case if accepted for publication and presentation at the Congress and in the promotion of the abstract/clinical case.
The recipients of the data are ESC Staff who process the submissions and the ESC Committees and volunteers involved in the abstract and clinical case programme. Data collected will be kept for 20 years. Transfer of personal data to ESC Staff, contractors as well as other ESC related scientific organisations occurs for production, promotion and dissemination of the Congress Content. In accordance with the chapter 3 of the European Regulation 2016/679 with regards to data protection, you have the right to request from ESC, access to and rectification or erasure of your personal data or restriction of processing concerning your data or to object to processing as well as the right to data portability. This is done thru withdrawal of the abstract/clinical case according to the terms and conditions of withdrawal.
For data privacy concerns, please contact (Kindly note that a proof of identity will be required during the process through a secured link) -
Data Privacy - European Society of Cardiology
2035 Route des Colles
CS 80179 Biot
06903 SOPHIA ANTIPOLIS CEDEX, France
Or by email to firstname.lastname@example.org
You have the right to lodge a complaint with a supervisory authority, and for information, ESC has appointed a Data Protection Officer that you can reach at email@example.com
Applicable law - All the rules pertaining to the present submission rules are governed by, and construed in accordance with, the laws of France without regard to any conflicts of laws principles thereof that would require the application of the law of any other jurisdiction. Any disputes arising in relation hereto shall be submitted to the exclusive jurisdiction of the French Tribunal Judiciaire located in Grasse, France.
The ESC reserves the right to make changes to the Abstract and Clinical Case submission rules based on the Covid-19 situation and convention centre restrictions/protocols/requirements; and/or in case of exceptional/Force Majeure events (defined as unforeseeable and irresistible events beyond the control of the ESC, such as natural disasters, war, civil unrest, coup d'Etat….). Any update or change will be posted on the ESC website.
If you have difficulties in submitting your abstract(s)/clinical case(s) or if you need any further information, please contact us at firstname.lastname@example.org.